School of Immunity and Infection, University of Birmingham, Birmingham, UK.
Clin Exp Allergy. 2013 Aug;43(8):941-9. doi: 10.1111/cea.12134.
Beta lactams (BL) are the most widely prescribed antibiotics in the UK and the commonest cause of hypersensitivity reactions. There are no UK guidelines for BL testing and the most relevant guidelines were devised by the European Network for Drug Allergy (ENDA) on behalf of the European Academy of Allergy and Clinical Immunology.
Delivery of allergy services differs across Europe, so this survey was designed to investigate how closely UK practice adhered to these guidelines.
An online survey, using surveymonkey.com software, was sent to all consultants offering an allergy service in the UK and who were members of either BSACI or 'Travellers' (Immunology consultant group).
The response rate was 48% (n=81/165) and BL allergy testing was undertaken by 78% of respondents. All responders requested SsIgE, although four responders stated they rarely requested. Skin testing was undertaken by 87% of respondents who perform beta lactam testing with 17% undertaking skin prick testing (SPT) only, 77% SPT followed by intra-dermal testing (IDT) if the former were negative or indeterminate and 6% SPT and IDT in all cases. The drugs, doses and protocols for skin testing varied considerably. Drug provocation testing was undertaken by 87% of respondents who undertake beta lactam testing with significant heterogeneity in protocols. Respondents that investigated ≤ 20 patients per year demonstrated lower adherence to ENDA recommendations compared to those who saw > 20. Following positive testing, 79% advised avoidance of all penicillins only and the remainder advised additional drug avoidance.
This survey revealed variation in the investigation and management of BL hypersensitivity in the UK with some centres reporting procedures that could potentially put patients at risk of anaphylaxis if allergy was falsely excluded. This survey highlights an urgent need for evidence based national guidelines and standardisation of practice.
β-内酰胺类抗生素(BL)是英国应用最广泛的抗生素,也是最常见的过敏反应原因。英国没有 BL 检测指南,最相关的指南是由欧洲过敏与临床免疫学会(EAACI)旗下的欧洲药物过敏网络(ENDA)制定的。
欧洲各地的过敏服务提供方式存在差异,因此这项调查旨在研究英国的实践与这些指南的贴合程度。
使用 surveymonkey.com 软件向英国所有提供过敏服务且是英国过敏协会(BSACI)或“旅行者”(Immunology consultant group)成员的顾问发送了一份在线调查。
应答率为 48%(n=81/165),78%的应答者进行 BL 过敏检测。所有应答者均要求检测特异性 IgE(sIgE),尽管有 4 名应答者表示他们很少要求检测 sIgE。87%进行 BL 检测的应答者进行皮肤试验,其中 17%仅进行皮肤点刺试验(SPT),77%如果 SPT 为阴性或不确定,则进行 SPT 后皮内试验(IDT),6%在所有情况下进行 SPT 和 IDT。皮肤试验的药物、剂量和方案差异很大。87%进行 BL 检测的应答者进行药物激发试验,其方案存在显著差异。每年调查≤20 例患者的应答者比调查>20 例患者的应答者对 ENDA 建议的遵从度较低。阳性检测后,79%建议避免使用所有青霉素,其余建议避免使用其他药物。
这项调查显示,英国 BL 过敏的调查和管理存在差异,一些中心报告的程序如果过敏被错误排除,可能会使患者面临过敏反应的风险。这项调查突出表明迫切需要基于证据的国家指南和实践标准化。